ImmunityBio Corp - IBRX Net earnings per share for the last four quarters

Official company branding of ImmunityBio Corp (IBRX)

ImmunityBio, Inc. (IBRX) is developing an immune cell activation platform to combat tumors within the B2B segment. The YoY change in EPS on a rolling 12-month basis, as reported by GURU.Markets quotes, shows that the latest figure stands at -110.20. Patrick Soon-Shiong is implementing innovative therapy methods while taking bold scientific risks. Diversified international operators ensure supply stability, eliminating logistical disruptions.

ImmunityBio (IBRX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/10/2026

IBRX (ImmunityBio Corp): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart immunitybio.com|IBRX - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization ImmunityBio Inc|IBRX - Total Company Value
- book value of equity indicators:
Accounting Value per Share ImmunityBio|IBRX - Company Book Value|Market Cap to Net Assets Ratio immunitybio.com|IBRX - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital ImmunityBio, Inc.|IBRX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio NantKwest|IBRX - Company Debts|Debts to Book Value ImmunityBio Inc|IBRX - Company Long-Term Liabilities|Short-Term Indebtedness ImmunityBio|Intermediate Liquidity Ratio immunitybio.com
- earnings and market multiples details:
IBRX - Net Profit|Expected Net Income ImmunityBio, Inc.|IBRX - P/E Multiple|Projected Price to Earnings Ratio ImmunityBio Inc|IBRX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation ImmunityBio Inc|IBRX - Operating profit EBITDA|Net earnings per share (EPS TTM) ImmunityBio|IBRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months immunitybio.com|IBRX - Net earnings per share growth this year|Expected net earnings per share growth next year ImmunityBio, Inc.
Initial company analysis:IBRX, immunitybio.com
Mass-produced product of immunitybio.com

Earnings per share dynamics determine the financial resilience of ImmunityBio, Inc. (IBRX) amid fierce competition with global pharma behemoths whose budgets could stifle the company's innovations. By analyzing the annual EPS growth rate over the last 12 months, an investor can observe a rolling increase in net income that offsets quarterly reporting gaps, allowing for the timely recognition of business weakening and preventing the overpayment for the asset.

Direct competitors

Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Inc CMPX|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|Sensei Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters therivabio.com TOVX|gritstonebio.com (GRTS) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Kineta Inc|Earnings per share for the last twelve months NexImmune Corp|Net earnings per share for the last 12 months Turnstone Biologics Corporation (TSBX)|Net earnings per share for the last 12 months VCNX (Vaccinex, Inc.)|Net earnings per share (EPS TTM) harpoontx.com (HARP)